share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(6.65%)

SEC announcement ·  Feb 13 18:23
Summary by Moomoo AI
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more